Dongfeng and Maxion Wheels Hold Groundbreaking Celebration for New Passenger Car Premium Aluminum Wheel Plant
Maxion Wheels, the world’s largest wheel manufacturer, with its new joint venture partner, Dongfeng Motor Parts and Components Group, held a groundbreaking ceremony on June 6, 2019 at the future site of their 22,000 square meters plant in Suizhou, China. The new company, Dongfeng Maxion Wheels Co., Ltd., was honored to share this important milestone with its distinguished guests including: government officials and company dignitaries, customers, suppliers and associates.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190607005238/en/
Dongfeng and Maxion Wheels celebrate the formation of their new joint venture and its future passenger car aluminum wheel plant with a groundbreaking ceremony on June 6, 2019 in Suizhou, China. (Photo: Business Wire)
“With our new partner, Dongfeng Motor Parts and Components, this plant will serve future demand from global and Chinese vehicle manufacturers for locally-produced aluminum car wheels,” said Pieter Klinkers, Chief Executive Officer, Maxion Wheels. “Through our partnership with one of China’s largest automotive parts companies, we can quickly bring global aluminum wheel making expertise to the biggest vehicle market in the world.”
Kai Kronenberg, Vice President and Chief Representative Officer for Maxion Wheels in China added, “We estimate start of production to be by the end of 2020, with plans to produce two million die cast, bright-machined wheels a year.”
ABOUT MAXION WHEELS
Maxion Wheels, a division of Iochpe-Maxion S.A., is a leading wheel manufacturer for passenger cars, light trucks, buses, commercial trucks, and trailers. The Company also produces wheels for agriculture, as well as other off-highway applications. With more than 100 years of wheel-making experience and 10,000 employees globally, Maxion is the world's largest wheel manufacturer, producing almost 60 million wheels per year. The Company serves its global OEM customers from a vast, globally-connected network that includes 23 plants in 12 countries, and state-of-the-art technical centers in the Americas, Europe, and Asia. To learn more, please visit Maxion Wheels’ website at www.maxionwheels.com.
ABOUT DONGFENG MOTOR PARTS AND COMPONENTS GROUP
Dongfeng Motor Parts and Components Group Co., Ltd., headquartered in Shiyan, Hubei province, is a subsidiary of Dongfeng Motor Co., Ltd., and specialized in research & development, manufacturing and sales of auto parts, including chassis systems, cabin and body systems, electric drive systems, braking and intelligent driving systems, powertrain systems, thermal management systems, powertrain systems and lightweight technologies.
Dongfeng Motor Parts and Components Group Co. Ltd. has 14,000 employees, 38 subsidiaries, including a listed company named Dongfeng Electronic Technology Co., Ltd. (Stock Code: 600081), 1 overseas company and 14 joint ventures. The annual sales of the Group in 2018 were RMB 18 billion, which make it one of the largest auto parts suppliers in China.
MAXION WHEELS MEDIA CONTACT:
Global Director, Marketing and Communications
Tel: +1 (248) 916-2477
DONGFENG MEDIA CONTACT:
Chief of Communication, Corporate Culture Communication Department
Dongfeng Motor Parts and Components Group Co. Ltd.
Tel: +86 (0719) 8221814
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Assimoco Group Selects Moody’s Analytics SolvencyWatch ™ Solution29.5.2020 11:00:00 CEST | Press release
Moody’s Analytics, a global provider of financial intelligence, today announced that its software has been selected by Assimoco Group, an Italian insurance group and the insurance provider for the Italian Cooperative Movement since 1978. Assimoco Group will use the Moody’s Analytics SolvencyWatch solution to monitor key solvency metrics. Powered by Moody’s Analytics award-winning modeling capabilities, the SolvencyWatch solution quickly calculates an insurer’s assets and liabilities to reflect the latest market conditions, enabling chief risk officers (CROs) to monitor their solvency position in real time. The tool’s intuitive dashboard allows CROs and risk teams to visualize the impact on crucial solvency metrics under changes to market and non-market risks, and communicate to stakeholders what is driving changes in those metrics. “The Moody’s Analytics SolvencyWatch solution will allow us to monitor our solvency position frequently, accurately, and cost effectively,” said Ruggero Fre
Wipro Appoints Thierry Delaporte as CEO & Managing Director29.5.2020 07:21:00 CEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced the appointment of Thierry Delaporte as the Chief Executive Officer and Managing Director of the company, effective July 6, 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200528005916/en/ Thierry Delaporte (Photo: Business Wire) Until recently, Thierry Delaporte was the Chief Operating Officer of Capgemini Group and a member of its Group Executive Board. During his twenty-five year career with Capgemini, he held several leadership roles including that of Chief Executive Officer of the Global Financial Services Strategic Business Unit, and head of all global service lines. He also oversaw Capgemini’s India operations, and led the group’s transformation agenda, conceptualizing and driving several strategic programs across various business units. “I am delighted to
Ipsen Appoints David Loew as Chief Executive Officer29.5.2020 07:05:00 CEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200528005876/en/ David Loew, CEO at Ipsen as of July 1st 2020 (Photo: Business Wire) Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its Board of Directors has appointed David Loew as its new Chief Executive Officer (CEO) and as Board member. The CEO appointment will take effect on July 1st, 2020. The Board of Directors expresses its gratitude to Aymeric Le Chatelier, who steered the group very well in an exceptionally challenging environment and who will remain in the role of acting CEO until July 1st, 2020 and will continue in his role of Chief Financial Officer. David Loew will be based at Ipsen’s headquarters in Boulogne-Billancourt, France. His mission will be to ensure Ipsen’s continued growth and to advance its pipeline via a long-term value-adding external innovation strategy, while fostering a culture of entrepreneurship, agility and patient-cent
New data show first-line triplet regimen of pembrolizumab, Herzuma ® (biosimilar trastuzumab) and chemotherapy are effective in treatment of HER2-positive advanced gastric cancer29.5.2020 01:01:00 CEST | Press release
Data presented today as part of the ASCO20 Virtual Scientific Program show that a first-line triplet regimen comprising of pembrolizumab, Herzuma®(biosimilar trastuzumab) and chemotherapy is effective in patients with HER2-positive advanced gastric cancer (AGC). The PANTHERA trial (a phase Ib/II study of first line pembrolizumab in combination with trastuzumab, capecitabine, and cisplatin in HER2-positive gastric cancer), sponsored by Celltrion Inc. and MSD, is investigating the potential of a first-line immunotherapy/chemotherapy combination with biosimilar trastuzumab. This is in light of a growing body of evidence that the immune system contributes to the therapeutic effects of monoclonal antibodies such as biosimilar trastuzumab in treating solid tumours.1 A total of 43 patients were treated with a median follow up of 18 months. Patients were treated with pembrolizumab 200mg via IV infusion D1,biosimilar trastuzumab 6mg/kg (after 8mg/kg load) D1, capecitabine 1000mg/m2 bid D1-D14 a
European Commission Releases Takeda From Commitment to Divest Shire’s Pipeline Compound SHP64729.5.2020 01:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announces that on May 28, the European Commission (the “EC”) has released Takeda from the obligation to divest the pipeline compound SHP647 and certain associated rights (“SHP647”), a commitment that was provided by Takeda to secure regulatory clearance of its acquisition of Shire plc (“Shire”). Takeda will discontinue the current SHP647 clinical trial program, and it will be providing all eligible trial participants with the opportunity to have continued access to SHP647 in a post-trial access (“PTA”) study. In addition, subject to obtaining trial participant consents and the satisfaction of regulatory and ethical considerations, Takeda will make SHP647 clinical trial data and biosamples available to the scientific community through the Crohn’s & Colitis Foundation (“Foundation”). Takeda announced on November 20, 2018, that the EC approved its proposed acquisition of Shire (the “Acquisition”). The EC’s appr
Jefferies' Clients, Employees and Shareholders Contribute $9,250,000 to Over 85 Charities for Coronavirus Relief in Memory of Peg Broadbent28.5.2020 18:02:00 CEST | Press release
Jefferies announced today a total donation to over 85 different charities of $9.25 million as a result of a firmwide global effort to raise money to honor the memory of their late CFO Peg Broadbent, who was a victim of this terrible disease. Through the firm’s Global Coronavirus Relief Charity Day held May 27th, Jefferies’ clients helped to generate $7.65 million in donated net trading commissions. In addition, Jefferies as a firm will donate $1 million directly, and voluntary donations from Jefferies’ 3,822 employees totaled $600,000. “We could not be prouder of our entire Jefferies family for raising $9.25 million and are greatly appreciative of the incredible partnership our clients have shown us in supporting our fight against Covid-19. The full $9.25 million will be wired today and go to direct relief efforts at over 85 worthy global charities who are each in the front lines helping those most impacted by the Coronavirus global pandemic. We went broadly to a large number of charit